The brand products had combined annual sales of $1.6bn in the US, based on IMS sales data for the 12 months ended June 2010.
Mumbai, India-based Lupin Limited produces generic and branded formulations and active pharmaceutical ingredients for the developed and developing markets of the world.
Lupin operates in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, in addition to Anti-TB and Cephalosporins.